Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes

[1]  W. Ogawa,et al.  Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. , 2021, Biochemical and biophysical research communications.

[2]  E. Fontaine,et al.  The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells , 2021, Endocrinology, diabetes & metabolism.

[3]  D. Moller,et al.  Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats , 2020, Endocrinology, diabetes & metabolism.

[4]  Jing-mei Liu,et al.  Comprehensive analysis of partial epithelial mesenchymal transition‐related genes in hepatocellular carcinoma , 2020, Journal of cellular and molecular medicine.

[5]  D. Moller,et al.  Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action , 2020, bioRxiv.

[6]  Subin Kim,et al.  A review of phenformin, metformin, and imeglimin , 2020, Drug development research.

[7]  S. O’Rahilly,et al.  GDF15 mediates the effects of metformin on body weight and energy balance , 2019, Nature.

[8]  Amogelang R. Raphenya,et al.  Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss , 2019, Nature Metabolism.

[9]  F. Wondisford,et al.  Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK , 2019, Cell reports.

[10]  B. Viollet,et al.  Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus , 2019, Nature Reviews Endocrinology.

[11]  Shuai Jiang,et al.  Mitochondrial electron transport chain, ROS generation and uncoupling (Review) , 2019, International journal of molecular medicine.

[12]  E. Fontaine.  Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences , 2018, Front. Endocrinol..

[13]  F. Sicheri,et al.  Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase , 2018, Nature Medicine.

[14]  Haiyang Xie,et al.  Metallothionein 1 family profiling identifies MT1X as a tumor suppressor involved in the progression and metastastatic capacity of hepatocellular carcinoma , 2018, Molecular carcinogenesis.

[15]  D. Richardson,et al.  Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[16]  M. Birnbaum,et al.  Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models , 2018, EBioMedicine.

[17]  B. Viollet,et al.  AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development , 2018, EBioMedicine.

[18]  L. Ford,et al.  Repurposing metformin for the prevention of cancer and cancer recurrence , 2017, Diabetologia.

[19]  B. Viollet,et al.  Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. , 2017, Cell metabolism.

[20]  K. Petersen,et al.  Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. , 2016, American journal of physiology. Endocrinology and metabolism.

[21]  G. Pacini,et al.  Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[22]  F. Wondisford,et al.  Metformin action: concentrations matter. , 2015, Cell metabolism.

[23]  J. M. Kumar,et al.  Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis , 2014, Diabetes.

[24]  E. Fontaine,et al.  Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model , 2014, Diabetes.

[25]  D. Hardie.  AMPK--sensing energy while talking to other signaling pathways. , 2014, Cell metabolism.

[26]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[27]  J. Cha,et al.  Metformin Suppresses Lipopolysaccharide (LPS)-induced Inflammatory Response in Murine Macrophages via Activating Transcription Factor-3 (ATF-3) Induction* , 2014, The Journal of Biological Chemistry.

[28]  B. Viollet,et al.  Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP , 2016 .

[29]  H. Lebovitz,et al.  Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients , 2012, Diabetes, obesity & metabolism.

[30]  B. Viollet,et al.  Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status , 2011, Diabetologia.

[31]  I. Ben-Sahra,et al.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.

[32]  X. Leverve,et al.  Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes , 2011 .

[33]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[34]  L. Kifle,et al.  Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. , 2006, Cell metabolism.

[35]  X. Leverve,et al.  Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. , 2005, Diabetes.

[36]  J. Turrens,et al.  Mitochondrial formation of reactive oxygen species , 2003, The Journal of physiology.

[37]  D. Friend,et al.  TTTTTTTTT ISOLATED RAT LIVER PARENCHYMAL CELLS A Biochemical and Fine Structural Study , 2003 .

[38]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[39]  M. Kasuga,et al.  Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. , 2002, Diabetes.

[40]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[41]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[42]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[43]  C. Bailey,et al.  Accumulation of metformin by tissues of the normal and diabetic mouse. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  D. Friend,et al.  HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS , 1969, Journal of Cell Biology.